Sensyne Health PLC - Oxford, England-based clinical technology using artificial intelligence - Says MagnifEyeO AI software granted Authorisation of Special Use by UK watchdog Medicines & Healthcare Products Regulatory Agency. "MagnifEye has demonstrated that it has the potential to play an important role in Covid-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation," Chief Executive Officer Paul Drayson says. System uses AI to produce accurate results from lateral flow diagnostic tests.
Current stock price: 161.00 pence
Year-to-date change: up 43%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.